No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Oscotec Inc. is a biopharmaceutical company specializing in the discovery and development of novel therapeutic drugs. Its primary focus lies in advancing a pipeline of investigational medicines, including a SYK inhibitor currently in Phase IIa clinical trials for the treatment of both rheumatoid arthritis and immune thrombocytopenia. Another key asset is an FLT3 inhibitor, undergoing Phase I clinical evaluation for acute myeloid leukemia. The company is also developing an EGFR double mutation inhibitor aimed at non-small cell lung cancer, and an Anti-Tau antibody in the preclinical stage for Alzheimer's disease. Beyond its pharmaceutical endeavors, Oscotec Inc. diversifies its offerings with a range of dental health products, such as bone graft materials like InduCera, BioCera-F, and SynCeraII, alongside membranes including LysoGide and CollaGuide. Additionally, it markets functional ingredients designed to address specific health concerns, such as OPB for osteoporosis, AIF for arthritis, SGA for enhancing bone growth, and PRF-K for periodontal conditions. Established in 1988, the company, originally known as Oscotec Co., Ltd, adopted its current name, Oscotec Inc., in June 1999. It is headquartered in Seongnam, South Korea.
www.oscotec.comNo one on the platform currently holds 039200.KQ.
No tracked institution reports a position in 039200.KQ as of their last filing.
No one on the platform has traded 039200.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 29.5% | — | — | — | ||
| Rev. Growth % | 193.6% | 18.1% | ||||
| Profit Margin % | 52.6% | -318.1% | -234.8% | |||
| Free Cash Flow Margin % | 7.5% | -312.9% | -215.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $84.0B | +23.5% | $639.00 | $639.00–$639.00 | — | 1 |
| 2027 | $192.0B | +128.6% | $2494.00 | $2494.00–$2494.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-14 | $-324.20 | $958.14 | +395.5% |
| 2026-05-15 | $-324.20 | $1590.00 | +590.4% |
| 2025-11-11 | $-324.20 | $-13.00 | +96.0% |
| 2025-08-12 | $-240.30 | $-48.17 | +80.0% |
| 2025-05-14 | $-311.74 | $-155.35 | +50.2% |
| 2025-02-26 | $-245.49 | $-127.13 | +48.2% |
| 2024-11-13 | $-324.20 | $442.00 | +236.3% |
| 2024-08-14 | $-324.20 | $-149.44 | +53.9% |
| $39150.00 |
| -0.25% |
| $1.73T |
| — |
| 069620.KSDaewoong pharmaceutical Co.,Ltd | $108700.00 | -1.00% | $1.25T | — |
| 185750.KSChong Kun Dang Pharmaceutical Corp. | $65750.00 | -0.23% | $866.3B | — |
Source: Financial Modeling Prep · peers by sector/industry